A Study Comparing Efficacy And Utility Of Pre-Emptive Day 4 Plerixafor-Based Mobilization Algorithm Versus Standard-Dose Plerixafor Algorithm In Patients With Multiple Myeloma Undergoing Peripheral Blood Progenitor Cell (PBPC) Mobilization for Autologous Hematopoietic Stem Cell Transplantation (ASCT).
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2017
Price : $35 *
At a glance
- Drugs Plerixafor (Primary) ; Filgrastim
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Therapeutic Use
- 30 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.